Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Treatment options for small cell lung cancer are limited, as are options for other DLL3-associated tumors such as neuroendocrine prostate cancer.